These data indicated that LyP-1-labeled liposomes were excellent nanoscale carriers for delivering DOX into lymphatic metastatic tumors, significantly destroying tumor-associated lymphatic vessels, inhibiting LN metastases and decreasing damage to the injection site. This evidence concerns the gene PTPN22 and neoplasm.